| scholarly article | Q13442814 |
| P50 | author | Karl Herholz | Q67216139 |
| P2093 | author name string | Federica Agosta | |
| Flavio Nobili | |||
| Marina Boccardi | |||
| Javier Arbizu | |||
| Zuzana Walker | |||
| Alexander Drzezga | |||
| Femke Bouwman | |||
| Peter Nestor | |||
| Giovanni Battista Frisoni | |||
| Daniele Altomare | |||
| Cristina Festari | |||
| Stefania Orini | |||
| P2860 | cites work | Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q24595802 |
| Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860537 | ||
| Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families | Q27860677 | ||
| Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia | Q29397661 | ||
| Clinical and biomarker changes in dominantly inherited Alzheimer's disease | Q29619940 | ||
| Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework | Q30235199 | ||
| Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease | Q30557788 | ||
| Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. | Q31063014 | ||
| Positron emission tomography in familial Alzheimer disease. | Q53200766 | ||
| Dissociating behavioral disorders in early dementia—An FDG-PET study | Q61871245 | ||
| ??? | Q64866542 | ||
| 18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons | Q33740879 | ||
| Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism | Q33852093 | ||
| Hypometabolism in Alzheimer-affected brain regions in cognitively healthy Latino individuals carrying the apolipoprotein E epsilon4 allele | Q34145373 | ||
| Biochemical, neuropathological, and neuroimaging characteristics of early-onset Alzheimer's disease due to a novel PSEN1 mutation | Q34555722 | ||
| Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease | Q34606557 | ||
| The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function | Q34674417 | ||
| Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. | Q34727992 | ||
| Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease | Q35029086 | ||
| A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease | Q35049917 | ||
| Correlations between FDG PET glucose uptake-MRI gray matter volume scores and apolipoprotein E ε4 gene dose in cognitively normal adults: a cross-validation study using voxel-based multi-modal partial least squares | Q35887041 | ||
| Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study | Q35900301 | ||
| Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies | Q36197614 | ||
| Early astrocytosis in autosomal dominant Alzheimer's disease measured in vivo by multi-tracer positron emission tomography | Q36265825 | ||
| A European multicentre PET study of fibrillar amyloid in Alzheimer's disease | Q36434858 | ||
| Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints | Q36661066 | ||
| The ups and downs of the posteromedial cortex: age- and amyloid-related functional alterations of the encoding/retrieval flip in cognitively normal older adults | Q36814521 | ||
| Cognitive reserve associated with FDG-PET in preclinical Alzheimer disease | Q36953075 | ||
| Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle-aged persons at 3 levels of genetic risk for Alzheimer disease | Q37098909 | ||
| Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings. | Q37283742 | ||
| Reduced FDG-PET brain metabolism and executive function predict clinical progression in elderly healthy subjects | Q37344722 | ||
| Three-year follow-up of a patient with early-onset Alzheimer's disease with presenilin-2 N141I mutation - case report and review of the literature | Q37346431 | ||
| A novel PSEN1 mutation (I238M) associated with early-onset Alzheimer's disease in an African-American woman | Q37678589 | ||
| Differential Risk of Incident Alzheimer's Disease Dementia in Stable Versus Unstable Patterns of Subjective Cognitive Decline | Q38377766 | ||
| Hippocampal hypometabolism in older adults with memory complaints and increased amyloid burden | Q38851607 | ||
| Guidance for the preparation of neurological management guidelines by EFNS scientific task forces - revised recommendations 2012. | Q39484458 | ||
| The value of PET in mild cognitive impairment, typical and atypical/unclear dementias: A retrospective memory clinic study | Q43030811 | ||
| A novel presenilin1 mutation (Q223R) associated with early onset Alzheimer's disease, dysarthria and spastic paraparesis and decreased Abeta levels in CSF. | Q43242655 | ||
| Brain metabolic differences between sporadic and familial Alzheimer's disease. | Q44634161 | ||
| Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment | Q47232869 | ||
| MR, (18)F-FDG, and (18)F-AV45 PET correlate with AD PSEN1 original phenotype | Q47880889 | ||
| Neurobiological correlates of depressive symptoms in people with subjective and mild cognitive impairment | Q48186091 | ||
| Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. | Q48380741 | ||
| Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation | Q48444836 | ||
| Positron Emission Tomography and Familial Alzheimer's Disease: A Pilot Study | Q48529173 | ||
| Complementarity of visual and voxel-based FDG-PET analysis to detect MCI-like hypometabolic pattern in elderly patients with hypertension and isolated memory complaints | Q48624528 | ||
| Plasma antioxidants and brain glucose metabolism in elderly subjects with cognitive complaints | Q48829714 | ||
| Metabolic correlates of Rey auditory verbal learning test in elderly subjects with memory complaints | Q48918141 | ||
| Time course of glucose metabolism in relation to cognitive performance and postmortem neuropathology in Met146Val PSEN1 mutation carriers. | Q51606008 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | positron emission tomography | Q208376 |
| diagnosis | Q16644043 | ||
| P304 | page(s) | 1487-1496 | |
| P577 | publication date | 2018-07-01 | |
| P1433 | published in | European Journal of Nuclear Medicine and Molecular Imaging | Q15708890 |
| P1476 | title | Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer's disease | |
| P478 | volume | 45 |
| Q59901866 | Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia |
| Q57178030 | Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia |
| Q53513882 | Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia. |
| Q53513944 | Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia. |
| Q64066636 | Neuroimaging and Neurolaw: Drawing the Future of Aging |
Search more.